Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
Curr Med Res Opin
; 36(11): 1813-1823, 2020 11.
Article
en En
| MEDLINE
| ID: mdl-32969741
ABSTRACT
AIMS:
This study assessed the real-world United States (US) treatment patterns and the associated economic burden in patients diagnosed with advanced hepatocellular carcinoma (HCC).METHODS:
The MarketScan database was used to identify patients newly diagnosed with HCC who received systemic therapy between 2011 and 2018 and continuously enrolled for ≥6 months (baseline period) prior and ≥1 month following HCC diagnosis. Treatment patterns (systemic and locoregional therapy), healthcare resource utilization, and costs were reported during follow-up.RESULTS:
The final sample included 1580 patients (median age, 61; 78% male; median follow up, 8.7 months). The most common first line of therapy (LOT) was sorafenib (78%). The median time from HCC diagnosis to start of sorafenib was 43 days, and the median duration of sorafenib therapy was 60 days. Only 17% of patients received second LOT, and non-sorafenib treatment use increased to 66% (mostly chemotherapy combination). Transarterial chemoembolization was the most commonly observed locoregional therapy prior to the first LOT. The multivariable-adjusted average all-cause total cost among sorafenib treated patients was $17,642 (95% CI $16,711-$18,558) per-patient per-month), of which $11,393 were HCC-specific.CONCLUSIONS:
In patients who received first-line therapy for HCC, the duration of therapy was short (potentially due to progression or tolerability). Most patients did not continue to second-line therapy. Despite the short duration of therapy, HCC patients still incur a high economic burden, and there is a need for more effective and tolerable treatments.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
Problema de salud:
1_financiamento_saude
Asunto principal:
Costos de la Atención en Salud
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
Tipo de estudio:
Health_economic_evaluation
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
/
Pregnancy
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Curr Med Res Opin
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos